Jane Street Group LLC trimmed its holdings in AstraZeneca plc (NYSE:AZN) by 33.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,181 shares of the company’s stock after selling 8,694 shares during the period. Jane Street Group LLC’s holdings in AstraZeneca were worth $596,000 at the end of the most recent reporting period.
A number of other large investors have also modified their holdings of the business. Ladenburg Thalmann Financial Services Inc. boosted its stake in AstraZeneca by 11.5% in the 4th quarter. Ladenburg Thalmann Financial Services Inc. now owns 37,904 shares of the company’s stock worth $1,318,000 after buying an additional 3,921 shares during the last quarter. NWQ Investment Management Company LLC boosted its stake in AstraZeneca by 3.0% in the 4th quarter. NWQ Investment Management Company LLC now owns 595,499 shares of the company’s stock worth $20,664,000 after buying an additional 17,624 shares during the last quarter. Teachers Advisors LLC boosted its stake in AstraZeneca by 7.1% in the 4th quarter. Teachers Advisors LLC now owns 991,956 shares of the company’s stock worth $34,421,000 after buying an additional 65,970 shares during the last quarter. Bain Capital Public Equity Management LLC acquired a new stake in AstraZeneca in the 4th quarter worth about $5,790,000. Finally, HBK Investments L P acquired a new stake in AstraZeneca in the 4th quarter worth about $812,000. 15.14% of the stock is currently owned by hedge funds and other institutional investors.
A number of brokerages have issued reports on AZN. BMO Capital Markets set a $40.00 price target on AstraZeneca and gave the stock a “buy” rating in a research note on Thursday, March 22nd. Zacks Investment Research upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, March 20th. ValuEngine upgraded AstraZeneca from a “buy” rating to a “strong-buy” rating in a report on Monday, March 19th. Jefferies Group upgraded AstraZeneca from a “hold” rating to a “buy” rating and raised their price objective for the stock from $28.43 to $36.70 in a report on Monday, March 19th. Finally, Leerink Swann raised their price objective on AstraZeneca from $36.00 to $38.00 and gave the stock a “market perform” rating in a report on Tuesday, February 6th. Three analysts have rated the stock with a sell rating, six have assigned a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $38.12.
AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, February 2nd. The company reported $1.30 EPS for the quarter, beating the consensus estimate of $0.44 by $0.86. The business had revenue of $5.78 billion for the quarter, compared to the consensus estimate of $5.49 billion. AstraZeneca had a return on equity of 34.74% and a net margin of 13.36%. The company’s revenue was up 3.4% on a year-over-year basis. During the same period last year, the business posted $1.21 EPS. equities analysts forecast that AstraZeneca plc will post 1.7 earnings per share for the current year.
The business also recently announced a semiannual dividend, which was paid on Monday, March 19th. Investors of record on Friday, February 16th were issued a dividend of $0.95 per share. The ex-dividend date of this dividend was Thursday, February 15th. This represents a dividend yield of 5.62%. AstraZeneca’s payout ratio is currently 32.01%.
ILLEGAL ACTIVITY NOTICE: This report was first published by Ticker Report and is owned by of Ticker Report. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3337382/astrazeneca-plc-azn-shares-sold-by-jane-street-group-llc.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.